Preclinical studies showed synergic anti-tumor activity of Rituximab and Fludarabin.Comparison of efficacy of FC with FCR regimens administered in first line therapy Manicure Kit and their influence on disease-free and overall survival in patients with B-cell Bike Parts - Bearings lymphocytic leukemia were the main goals of this retrospective study.It has been demonstrated that inclusion of Rituximab into the FC regimen improves outcome of patients with B-cell lymphocytic leukemia without significant increase of toxicity.